Topics

Latest "Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief?" News Stories

04:06 EST 21st November 2019 | BioPortfolio

Here are the most relevant search results for "Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief?" found in our extensive news archives from over 250 global news sources.

More Information about Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief? on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief? for you to read. Along with our medical data and news we also list Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief? Clinical Trials, which are updated daily. BioPortfolio also has a large database of Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief? Companies for you to search.

Showing "Diabetic Foot Ulcers Shorter Treatment Period Using Custom" News Articles 1–25 of 22,000+

Thursday 21st November 2019

Asklepios Kliniken: Revenue growth in first nine months of 2019

DGAP-News: Asklepios Kliniken / Key word(s): Quarterly / Interim Statement 21.11.2019 / 07:30 The issuer is solely responsible for the content of this announcement. Asklepios Kliniken: Revenue growth in first nine months of 2019 - Revenue up 4.0% at EUR 2,637 million - Number of patients increased by 10.7% to 1.86 million - Sharp rise in staff costs curbs earnings dev...


Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous 21.11.2019 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019 HALLE (SAALE), Germany, 21 November 2019 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), will publish its third quarter financ...

Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock

Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the treatment of septic shock and has enrolled the first patient in the trial. Nangibotide is a TREM-1 inhibitor peptide with the potential to restore ap...


Wednesday 20th November 2019

. @CRISPRTX and @VertexPharma Report First Data from Trials of Gene-Editing Treatment CTX001: http://ow.ly/55qA50xeXaO pic.twitter.com/vhuMtB09d1

. @CRISPRTX and @VertexPharma Report First Data from Trials of Gene-Editing Treatment CTX001: http://ow.ly/55qA50xeXaO  pic.twitter.com/vhuMtB09d1

New Milliman Report Highlights Continuing Barriers to Mental Health and Substance Use Disorder Treatment

Parity Implementation Coalition Concerned by Report's Findings of Lower Payments to Providers and Higher Out-of-Pocket Costs for Consumers as Compared to Medical/Surgical Treatment and Calls for Full Enforcement and Implementation of the Mental Health Parity and Addiction Equity Act WASHINGTON, DC (PRWEB) November 20, 2019 A report, “Addiction and Mental Health vs. Physical Health: Widening...

“The experience of having a foot there again was somewhat of a surreal experience,” says Jim Ewing says of his robotic limb — for example, his knee would move if he flexed his toes. Ewing’s experience is the subject of a new documentary, @Augmente

“The experience of having a foot there again was somewhat of a surreal experience,” says Jim Ewing says of his robotic limb — for example, his knee would move if he flexed his toes. Ewing’s experience is the subject of a new documentary, @Augmented_Film

Alnylam Gets FDA Nod for Rare Disease Drug

The FDA's approval of Alnylam's Gilvaari treatment is the first approval of its kind for acute hepatic porphyria. The post Alnylam Gets FDA Nod for Rare Disease Drug appeared first on Investing News Network.

Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension

NIC CEO, Employees Run the Extra Mile, Raise More Than $235,000 for St. Jude Children’s Research Hospital®

What started as a challenge quickly grew into a movement, impacting complete strangers in more ways than one and raising more than $235,000 for St. Jude. As the leader in digital government, NIC employees are used to helping citizens and governments across the country without much fanfare. The company’s behind-the-scenes work is what helps fuel its partner states’ interactions and relationsh...

College of American Pathologists and Taiwan Society of Clinical Pathologists Partner for Laboratory Education Program

Physicians and Laboratory Professionals Discuss Quality, Accreditation and Leading-Edge Testing Methods The practice of pathology—the medical field that studies and diagnosis disease while guiding treatment for patients—is constantly evolving to incorporate new technologies and practices to produce faster and more accurate laboratory test results. To help ensure laboratory professionals th...

Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow

Lucence, a genomic medicine company developing blood-based tests for cancer screening and treatment selection, announced this week the close of a $20 million Series A funding round led by IHH Healthcare. CEO and founder Min-Han Tan (pictured) says the investment will be used to scale the Singapore-based company’s clinical lab operations—notably in the US, with […]

2019 Throat Infection Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Throat Infection Clinical Trials Study provides complete list of trials completed, ongoing and planned for Throat Infection. It presents indepth analysis of Throat Infection clinical trials across markets and companies. The research work is for providing complete understanding into trends in Throat Infection. The report covers a key snapshot of trial trends, ...

Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease

EDISON, NJ / ACCESSWIRE / November 20, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver dise...

2019 Malignant Ascites Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Malignant Ascites Clinical Trials Study provides complete list of trials completed, ongoing and planned for Malignant Ascites. It presents indepth analysis of Malignant Ascites clinical trials across markets and companies. The research work is for providing complete understanding into trends in Malignant Ascites. The report covers a key snapshot of trial tren...

Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders. Upon completion of the acquisition, pursuant to the terms of...

Glaukos Announces Participation in Piper Jaffray Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019, at 2:30 p.m. EST in New York City. A live audio webcast for this e...

FDA Approves Alnylam’s Givlaari for Treatment of Adults with Acute Hepatic Porphyria

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved GIVLAARI™ (givosiran) injection for subcutaneous use for the treatment of adults with acute hepatic porphyria (AHP). AHP is a family of ultra-rare, genetic diseases characterized by debilitati...

Bristol-Myers Squibb Announces Opdivo Plus Yervoy Fails to Meet Primary Endpoint in its Phase 3 Melanoma Study

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced results for one of the co-primary endpoints from CheckMate -915, a randomized Phase 3 study evaluating  Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo alone for the adjuvant treatment of patients who have had a complete surgical removal of stage IIIb/c/d or stage IV (no evidence of...

Our ambition is to help improve the management, care and outcomes for the millions of people living with #COPD worldwide. Powerful stories like Colin and Stephanie’s reinforce our commitment to addressing critical unmet treatment needs. #WorldCOPDDaypic

Our ambition is to help improve the management, care and outcomes for the millions of people living with #COPD worldwide. Powerful stories like Colin and Stephanie’s reinforce our commitment to addressing critical unmet treatment needs. #WorldCOPDDay pic.twitter.com/etP0kbOzEf

The Rooted Alumni Program Benefits Clients on Their Life-long Recovery Journey

Promises Behavioral Health’s Rooted alumni program helps clients stay connected after initial care. BRENTWOOD, Tenn. (PRWEB) November 20, 2019 Promises Behavioral Health, a leading provider of addiction and mental health treatment, has developed an alumni program to help clients stay on track with their recovery after initial care. The Rooted alumni program will be a part of all 10 of the Promi...

Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)

− Framework Ties Payment for GIVLAARI to its Delivery of Patient Outcomes in the Real-World Setting - − Includes New Approach Designed for Ultra-Rare Diseases that Gives Participating Payers Greater Financial Certainty if Disease Prevalence is Higher Than Anticipated – - Discussions Underway with Leading Insurers and Agreement in Principle in Place with Harvard Pilgrim -

Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)

− GIVLAARI Approved for the Treatment of Adults with Acute Hepatic Porphyria (AHP) Based on ENVISION Phase 3 Study Results Showing Significant Reduction in the Rate of Porphyria Attacks in Patients with AHP – − FDA Approval Received in Less Than Four Months after New Drug Application (NDA) Filing Acceptance – − GIVLAARI Becomes Second RNAi Therapeutic from Alnylam Approved by FDA in...

More Appropriate Prostate Cancer Tx Seen at Multidisciplinary Clinic

WEDNESDAY, Nov. 20, 2019 -- Receiving care at a multidisciplinary (MultiD) clinic facilitates adherence to evidence-based national treatment guidelines for prostate cancer, according to a study published online Nov. 19 in Cancer. Chad Tang, M.D.,...

Boundless Bio Announces Publication in Nature Elucidating the Role of Extrachromosomal DNA (ecDNA) Structure in Cancer Biology

  A study co-authored by Boundless Bio scientific founders Paul Mischel, Vineet Bafna, Howard Chang, and Roel Verhaak describes new mechanisms by which the unique circular architecture of ecDNA drives aggressive cancer growth, resistance, and recurrence Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that research descri...

Lung Transplant Rejection Pipeline Drugs and Companies, Q2 2019 [Report Updated: 08042019] Prices from USD $1799

Summary Lung Transplant Rejection pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Lung Transplant Rejection RD activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.Extensive Coverage of Pipeline CandidatesThe Lung Transplant Rejection repo...


Quick Search

News Quicklinks